FDA awards EpiVax $1.1 million research contract

PROVIDENCE – Biotechnology company EpiVax Inc. received $1.1 million in funding Wednesday from the U.S. Food and Drug Administration to further research efforts in the field of informatics and immunology. The company has been pursuing development of a COVID-19 vaccine and personalized cancer vaccines. The FDA's Office of Generic Drugs in the Center of Drug…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -